Neuphoria Therapeutics (NEUP) EBT Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly EBT Margin of 15367.09% for Q2 2025, up 20515.95% quarter-over-quarter from 74.54% in Q1 2025.

Neuphoria Therapeutics (NEUP) EBT Margin (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported EBT Margin for 2 consecutive years, with 15367.09% the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.61 Bn	131.75 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	35.61%
3	Argenx Se	65.28 Bn	60.09 Bn	1.37 Bn	35.71%
4	Moderna	59.14 Bn	54.00 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.13 Bn	37.03 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.83 Bn	28.52 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.07 Bn	9.68 Bn	668.28 Mn	-25.06%
8	Insmed	27.54 Bn	26.38 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.31 Bn	26.47 Bn	-	12.09%
10	Neuphoria Therapeutics	21.64 Mn	2.20 Mn	-	-

Download Data